364 related articles for article (PubMed ID: 33030266)
1. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
2. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
Wen HN; He QF; Xiang XQ; Jiao Z; Yu JG
Thromb Res; 2022 Oct; 218():24-34. PubMed ID: 35985100
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
4. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
5. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.
Brings A; Lehmann ML; Foerster KI; Burhenne J; Weiss J; Haefeli WE; Czock D
Br J Clin Pharmacol; 2019 Jul; 85(7):1528-1537. PubMed ID: 30912163
[TBL] [Abstract][Full Text] [Related]
6. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
7. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Otsuka Y; Poondru S; Bonate PL; Rose RH; Jamei M; Ushigome F; Minematsu T
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):365-376. PubMed ID: 37344637
[TBL] [Abstract][Full Text] [Related]
9. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein.
Margelidon-Cozzolino V; Hodin S; Jacqueroux E; Delézay O; Bertoletti L; Delavenne X
J Pharmacol Exp Ther; 2018 Jun; 365(3):519-525. PubMed ID: 29572341
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
[No Abstract] [Full Text] [Related]
13. Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.
Kou W; Sodhi JK; Wu X; Benet LZ
Pharm Res; 2021 May; 38(5):795-801. PubMed ID: 33847849
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation.
Cirincione B; Kowalski K; Nielsen J; Roy A; Thanneer N; Byon W; Boyd R; Wang X; Leil T; LaCreta F; Ueno T; Oishi M; Frost C
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):728-738. PubMed ID: 30259707
[TBL] [Abstract][Full Text] [Related]
15. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Jacqueroux E; Mercier C; Margelidon-Cozzolino V; Hodin S; Bertoletti L; Delavenne X
Fundam Clin Pharmacol; 2020 Feb; 34(1):109-119. PubMed ID: 31411766
[TBL] [Abstract][Full Text] [Related]
16. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
17. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
18. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Grymonprez M; Carnoy L; Capiau A; Boussery K; Mehuys E; De Backer TL; Steurbaut S; Lahousse L
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):722-730. PubMed ID: 37791408
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
20. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Cheong EJY; Teo DWX; Chua DXY; Chan ECY
Drug Metab Dispos; 2019 Nov; 47(11):1291-1306. PubMed ID: 31506301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]